ATLASUltragenyx Pharmaceutical (RARE) earnings date: Nov 3, 2026
Ultragenyx Pharmaceutical (RARE) reports earnings for the quarter ended Sep 30, 2026 on Tue, Nov 3, 2026, after the close. Analysts expect EPS of -$1.15.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on RARE
| Last price | $16.32 (+1.4%) |
|---|---|
| Normal 1-day range (±1σ) | ±4.5% |
| Earnings beat history | Beat the EPS estimate in 2 of the last 5 reports |
These figures come from the same calibrated model and valuation as the Ultragenyx Pharmaceutical stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Ultragenyx Pharmaceutical reports on Nov 3, 2026. One email the day before, with ATLAS’s read on Ultragenyx Pharmaceutical. You can switch it off at any time.
Alert me before RARE reportsFree to start. Creating an account takes under a minute.
Notify me when Ultragenyx Pharmaceutical reports
Track RARE free Add Ultragenyx Pharmaceutical to a free ATLAS watchlist and see its next report date in one place.
RARE earnings at a glance
| Next report (confirmed) | Tue, Nov 3, 2026 |
|---|---|
| Time | After the close |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$1.15 |
| Last report | Aug 4, 2026 · Beat |
| Beat rate (last 5 reports) | 2 of 5 (40%) |
| Average EPS surprise | +1.5% |
| Average move around a report | ±5.1% (last 5) |
| Sector | Healthcare · Biotechnology |
Ultragenyx Pharmaceutical earnings history: last 5 reports
Ultragenyx Pharmaceutical last reported on Aug 4, 2026: EPS of -$0.90 against an estimate of -$1.00 (+10.0% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 4, 2026 | -$1.00 | -$0.90 | +10.0% | Beat | -0.4% |
| May 5, 2026 | -$1.46 | -$1.54 | -5.5% | Miss | +4.5% |
| Feb 12, 2026 | -$1.17 | -$1.29 | -10.3% | Miss | -14.1% |
| Jan 28, 2026 | $1.03 | $1.03 | 0.0% | In line | -1.4% |
| Nov 19, 2025 | $3.21 | $3.63 | +13.1% | Beat | -5.0% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for RARE
See the fair value, the probability range and the earnings history of Ultragenyx Pharmaceutical on its ATLAS page.
Ultragenyx Pharmaceutical (RARE) stock analysisPlans from €3.99 a month.
Ultragenyx Pharmaceutical earnings: frequently asked questions
When does Ultragenyx Pharmaceutical (RARE) report earnings?
Ultragenyx Pharmaceutical is scheduled to report on Tuesday, November 3, 2026, after the close. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for RARE?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$1.15 per share (USD). Estimates can change before the report.
How often does RARE beat earnings estimates?
Of its last 5 reports with a recorded result, Ultragenyx Pharmaceutical beat the EPS estimate 2 times; the average surprise was +1.5%. Past results do not predict the next one.
How much does RARE move around earnings?
Over its last 5 reports the stock moved an average of 5.1% (absolute, from the close before the report day to the close after it), and finished higher 1 of 5 times.
Did Ultragenyx Pharmaceutical beat earnings estimates last quarter?
Ultragenyx Pharmaceutical last reported on Aug 4, 2026: EPS of -$0.90 against an estimate of -$1.00 (+10.0% surprise), a beat.
How much does RARE usually move in a day?
On a normal trading day the ATLAS model puts RARE’s one-day range at about ±4.5%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Tue, Nov 3, 2026
Educational information, not investment advice. Disclaimer